{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:31:18Z","timestamp":1763634678322,"version":"3.45.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Denosumab, a potent antiresorptive agent targeting receptor activator of nuclear factor kappa-B ligand (RANKL), is increasingly used off-label in RANKL-mediated pediatric bone disorders, but concerns remain regarding rebound hypercalcemia and altered bone modeling and remodeling. This study describes clinical, biochemical, and radiological features of metaphyseal sclerotic band fractures in children on denosumab and assesses risk factors with focus on timing and occurrence of rebound hypercalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective multicenter study. Clinical, biochemical, and X-ray data were reviewed. High-resolution peripheral quantitative computed tomography (HR-pQCT) and micro-finite element analysis were performed in 1 case to assess bone microarchitecture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five pediatric patients (aged 7-18 years) were included: 4 received denosumab for RANKL-mediated bone lesions, and 1 for secondary osteoporosis. Fractures occurred 1.5-7.7 years after starting denosumab, involving the distal radius, ulna, femur, clavicle, and rib. All followed low- or moderate-impact trauma and involved zones of metaphyseal sclerosis. Rebound hypercalcemia occurred in all patients (1 to &amp;gt;16 episodes); in 4 cases, it preceded the fracture by 0-4 months, while 1 case first developed hypercalcemia 3 weeks postfracture. HR-pQCT in a single patient revealed markedly increased trabecular volumetric bone mineral density and stiffness within the sclerotic band plus reduced estimated failure load. Bisphosphonates were used, albeit variably, for prevention or treatment of hypercalcemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Fractures through sclerotic metaphyseal bands may represent a distinct complication of denosumab therapy in children. Rebound hypercalcemia and fractures can co-occur, underscoring the need for close monitoring and management by pediatric bone specialists throughout treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf228","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:02:16Z","timestamp":1762520536000},"page":"622-630","source":"Crossref","is-referenced-by-count":0,"title":["Metaphyseal band fractures in pediatric patients treated with denosumab"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8579-1048","authenticated-orcid":false,"given":"Rodrigo","family":"Montero-Lopez","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz , 4021 Linz ,","place":["Austria"]},{"name":"Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Kepler University Hospital GmbH , 4020 Linz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4383-1552","authenticated-orcid":false,"given":"Karissa","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Queensland Children's Hospital , Brisbane, QLD 4101 ,","place":["Australia"]},{"name":"Child Health Research Centre, Faculty of Health, Medicine and Behavioral Sciences, The University of Queensland , Brisbane, QLD 4101 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Royal National Orthopaedic Hospital , Stanmore HA7 4LP ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D","family":"Chesover","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology and Diabetes, Great Ormond Street Hospital for Children NHS Foundation Trust , WC1N 3JH London ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahd","family":"Alshammri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ottawa, Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario , Ottawa, ON K1H 8L1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Mayrhofer","sequence":"additional","affiliation":[{"name":"Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Kepler University Hospital GmbH , 4020 Linz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Blaschitz","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz , 4021 Linz ,","place":["Austria"]},{"name":"Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Kepler University Hospital GmbH , 4020 Linz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queensland Children's Hospital, Children's Health Queensland Hospital, and Health Service , South Brisbane, QLD 4101 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Queensland Children's Hospital , Brisbane, QLD 4101 ,","place":["Australia"]},{"name":"Child Health Research Centre, Faculty of Health, Medicine and Behavioral Sciences, The University of Queensland , Brisbane, QLD 4101 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ottawa, Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario , Ottawa, ON K1H 8L1 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6304","authenticated-orcid":false,"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz , 4021 Linz ,","place":["Austria"]},{"name":"Centre for Growth and Osteology, Department of Paediatrics and Adolescent Medicine, Kepler University Hospital GmbH , 4020 Linz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"1","key":"2025112005264472200_lvaf228-B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11914-009-0004-5","article-title":"Denosumab: anti-RANKL antibody","volume":"7","author":"Miller","year":"2009","journal-title":"Curr Osteoporos Rep."},{"issue":"4","key":"2025112005264472200_lvaf228-B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep."},{"issue":"6","key":"2025112005264472200_lvaf228-B3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","article-title":"The clinical effectiveness of denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis","volume":"112","author":"Moshi","year":"2023","journal-title":"Calcif Tissue Int."},{"issue":"8","key":"2025112005264472200_lvaf228-B4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/nejmoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"author":"Amgen Canada Inc.","key":"2025112005264472200_lvaf228-B5"},{"author":"Amgen Canada Inc.","key":"2025112005264472200_lvaf228-B6"},{"issue":"5","key":"2025112005264472200_lvaf228-B7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1210\/clinem\/dgad657","article-title":"Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document","volume":"109","author":"Vanderniet","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2025112005264472200_lvaf228-B8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2025112005264472200_lvaf228-B9","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"2025112005264472200_lvaf228-B10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2025112005264472200_lvaf228-B11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1210\/clinem\/dgad732","article-title":"Safety and efficacy of denosumab in children with osteogenesis Imperfecta\u2014the first prospective comparative study","volume":"109","author":"Liu","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2025112005264472200_lvaf228-B12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00247-020-04651-y","article-title":"Dense sclerotic metaphyseal bands caused by denosumab therapy","volume":"50","author":"Dunnion","year":"2020","journal-title":"Pediatr Radiol."},{"issue":"9967","key":"2025112005264472200_lvaf228-B13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(14)61338-6","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"2025112005264472200_lvaf228-B14","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2014-3072","article-title":"Effect of denosumab on the growing skeleton in osteogenesis imperfecta","volume":"99","author":"Hoyer-Kuhn","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2025112005264472200_lvaf228-B15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1210\/jc.2013-3081","article-title":"Effects of denosumab treatment and discontinuation on human growth plates","volume":"99","author":"Wang","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2025112005264472200_lvaf228-B16","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00198-021-06002-5","article-title":"Denosumab for the treatment of primary pediatric osteoporosis","volume":"32","author":"Anastasilakis","year":"2021","journal-title":"Osteoporos Int"},{"key":"2025112005264472200_lvaf228-B17","doi-asserted-by":"publisher","first-page":"117501","DOI":"10.1016\/j.bone.2025.117501","article-title":"Rebound hypercalcaemia timing is associated with cumulative weight-based denosumab dose for central giant cell granuloma treatment in children despite a dose weaning regimen","volume":"197","author":"Chesover","year":"2025","journal-title":"Bone"},{"issue":"5","key":"2025112005264472200_lvaf228-B18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11914-023-00811-9","article-title":"Recommendations for high-resolution peripheral quantitative computed tomography assessment of bone density, microarchitecture, and strength in pediatric populations","volume":"21","author":"Gabel","year":"2023","journal-title":"Curr Osteoporos Rep."},{"issue":"10","key":"2025112005264472200_lvaf228-B19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.14670\/HH-18-355","article-title":"The hypertrophic chondrocyte: to be or not to be","volume":"36","author":"Hallett","year":"2021","journal-title":"Histol Histopathol."},{"issue":"5","key":"2025112005264472200_lvaf228-B20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"issue":"4","key":"2025112005264472200_lvaf228-B21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"14","key":"2025112005264472200_lvaf228-B22","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis Imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med."},{"issue":"4","key":"2025112005264472200_lvaf228-B23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.radcr.2017.07.003","article-title":"Pamidronate \u201czebra lines\u201d: a treatment timeline","volume":"12","author":"Loizidou","year":"2017","journal-title":"Radiol Case Rep."},{"issue":"7","key":"2025112005264472200_lvaf228-B24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Clinical vignette\u2014sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2025112005264472200_lvaf228-B25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1359\/JBMR.051207","article-title":"Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta","volume":"21","author":"Land","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2025112005264472200_lvaf228-B26","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2025112005264472200_lvaf228-B27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med."},{"issue":"4","key":"2025112005264472200_lvaf228-B28","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"issue":"3","key":"2025112005264472200_lvaf228-B29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000355111","article-title":"Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen","volume":"81","author":"Biggin","year":"2014","journal-title":"Horm Res Paediatr."},{"issue":"1","key":"2025112005264472200_lvaf228-B30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00247-011-2198-9","article-title":"Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers","volume":"42","author":"Harcke","year":"2012","journal-title":"Pediatr Radiol."},{"issue":"8","key":"2025112005264472200_lvaf228-B31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00198-007-0330-3","article-title":"Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?","volume":"18","author":"Ward","year":"2007","journal-title":"Osteoporos Int."},{"issue":"5","key":"2025112005264472200_lvaf228-B32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3109\/17453674.2015.1036339","article-title":"Bisphosphonate-associated peri-implant fractures: a new clinical entity?","volume":"86","author":"Lee","year":"2015","journal-title":"Acta Orthop."}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf228\/65251349\/lvaf228.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/5\/622\/65251349\/lvaf228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/5\/622\/65251349\/lvaf228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:26:49Z","timestamp":1763634409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/5\/622\/8317731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf228","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"type":"print","value":"0804-4643"},{"type":"electronic","value":"1479-683X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,30]]}}}